The Cholangitis drugs in development market research report provides comprehensive information on the therapeutics under development for Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cholangitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cholangitis and features dormant and discontinued products.
GlobalData tracks 33 drugs in development for Cholangitis by 32 companies/universities/institutes. The top development phase for Cholangitis is phase ii with 12 drugs in that stage. The Cholangitis pipeline has 29 drugs in development by companies and four by universities/ institutes. Some of the companies in the Cholangitis pipeline products market are: Ipsen, Catholic University of Daegu and Waterstone Pharmaceuticals (Wuhan).
The key targets in the Cholangitis pipeline products market include Ileal Sodium/Bile Acid Cotransporter, Peroxisome Proliferator Activated Receptor Alpha, and Sodium/Bile Acid Cotransporter.
The key mechanisms of action in the Cholangitis pipeline product include Peroxisome Proliferator Activated Receptor Alpha Agonist with three drugs in Phase II. The Cholangitis pipeline products include seven routes of administration with the top ROA being Oral and 11 key molecule types in the Cholangitis pipeline products market including Small Molecule, and Peptide.
Cholangitis overview
Cholangitis refers to inflammation of the bile ducts, which are tubes that carry bile from the liver to the gallbladder and small intestine. This condition can be acute or chronic and is often caused by a bacterial infection or blockage of the bile ducts. Cholangitis can cause a range of symptoms, which may include abdominal pain, particularly in the upper right side; jaundice (yellowing of the skin and eyes); fever and chills; nausea, vomiting, and loss of appetite; dark urine and pale stools; and generalized weakness or fatigue.
For a complete picture of Cholangitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
